Filing Flows › Agios Pharmaceuticals (AGIO) › Q3 2026 › vs Q2 2026
Agios Pharmaceuticals (AGIO) Q3 2026 vs Q2 2026 (quarter over quarter)
Agios Pharmaceuticals's revenue rose $10.6M (+24%) from $44.7M in Q2 2026 to $55.4M in Q3 2026.
Agios Pharmaceuticals, Q3 2026: revenue $55.4M (+330% year over year), operating margin -139.3%, net loss $65.0M, operating cash flow −$59.2M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $55.4M | $44.7M | $10.6M | +24% |
| Other income, net | $12.1M | $9.8M | $2.3M | +23% |
| Net loss | $65.0M | $101M | −$35.7M | -35% |
| Costs & expenses | $133M | $155M | −$22.8M | -15% |
| Operating costs | $133M | $155M | −$22.8M | -15% |
| Cost of revenue | $2.5M | $3.0M | −$471K | -16% |
| Research & development | $73.5M | $101M | −$27.3M | -27% |
| SG&A | $56.5M | $51.5M | $5.0M | +10% |
| Operating cash sources | $75.9M | $73.3M | $2.7M | +4% |
| Share-based compensation | $16.7M | $15.9M | $731K | +5% |
| Cash used in operations | $59.2M | $57.3M | $1.9M | +3% |
| Net loss absorbed | $65.0M | $101M | −$35.7M | -35% |
| Working capital & other | $10.9M | −$27.4M | $38.3M | — |
Questions
How much did Agios Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Agios Pharmaceuticals's revenue rose $10.6M (+24%) from $44.7M in Q2 2026 to $55.4M in Q3 2026.